CA2998065A1 - Methods for diagnosing and treating cancer - Google Patents

Methods for diagnosing and treating cancer Download PDF

Info

Publication number
CA2998065A1
CA2998065A1 CA2998065A CA2998065A CA2998065A1 CA 2998065 A1 CA2998065 A1 CA 2998065A1 CA 2998065 A CA2998065 A CA 2998065A CA 2998065 A CA2998065 A CA 2998065A CA 2998065 A1 CA2998065 A1 CA 2998065A1
Authority
CA
Canada
Prior art keywords
cancer
subject
ctc
blood sample
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2998065A
Other languages
English (en)
French (fr)
Inventor
Ju-Yu Tseng
Yen-Ru Chen
Chia-Ying Lee
Li-fan WU
Shin-Hang Wang
Jui-Lin Chen
Chwen-Cheng Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micareo Taiwan Co Ltd
Original Assignee
Micareo Taiwan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micareo Taiwan Co Ltd filed Critical Micareo Taiwan Co Ltd
Publication of CA2998065A1 publication Critical patent/CA2998065A1/en
Pending legal-status Critical Current

Links

Classifications

    • G01N33/575—
    • G01N33/57595—
    • G01N33/5753—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G01N33/57535—
    • G01N33/57557—
    • G01N33/5759—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
CA2998065A 2017-03-14 2018-03-14 Methods for diagnosing and treating cancer Pending CA2998065A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762471083P 2017-03-14 2017-03-14
US62/471,083 2017-03-14
US201762584634P 2017-11-10 2017-11-10
US62/584,634 2017-11-10

Publications (1)

Publication Number Publication Date
CA2998065A1 true CA2998065A1 (en) 2018-09-14

Family

ID=61868129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998065A Pending CA2998065A1 (en) 2017-03-14 2018-03-14 Methods for diagnosing and treating cancer

Country Status (8)

Country Link
US (1) US20180267046A1 (enExample)
EP (1) EP3376227B1 (enExample)
JP (1) JP2018155752A (enExample)
KR (1) KR20180105091A (enExample)
CN (1) CN108572255B (enExample)
AU (1) AU2018201819A1 (enExample)
CA (1) CA2998065A1 (enExample)
TW (1) TWI786095B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110142068B (zh) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法
CN111551718A (zh) * 2020-04-20 2020-08-18 山东第一医科大学(山东省医学科学院) 一种检测前列腺癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法
CN111562375B (zh) * 2020-04-20 2022-05-06 山东第一医科大学(山东省医学科学院) 一种检测胃癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法
TWI874453B (zh) * 2020-09-17 2025-03-01 日商細胞雲股份有限公司 使用末稍血循環腫瘤細胞之解析的癌症治療方法
RU2738563C1 (ru) * 2020-09-18 2020-12-14 Ен Джун Чой Способ прогноза малигнизации и ранней диагностики злокачественных опухолей
CN120559253A (zh) * 2025-05-30 2025-08-29 中国医学科学院肿瘤医院 Pd-l1阳性循环肿瘤细胞在肝癌免疫治疗中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096734A2 (en) * 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 antibody coupled bead assay for isolation and detection of circulating tumor cells in body fluids of melanoma and breast cancer patients
US20170242016A1 (en) * 2014-10-15 2017-08-24 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1

Also Published As

Publication number Publication date
JP2018155752A (ja) 2018-10-04
US20180267046A1 (en) 2018-09-20
TW201902534A (zh) 2019-01-16
EP3376227C0 (en) 2024-02-21
KR20180105091A (ko) 2018-09-27
EP3376227A1 (en) 2018-09-19
CN108572255A (zh) 2018-09-25
AU2018201819A1 (en) 2018-10-04
EP3376227B1 (en) 2024-02-21
TWI786095B (zh) 2022-12-11
CN108572255B (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
Cauley et al. Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings
EP3376227B1 (en) Methods for diagnosing and treating cancer
Li et al. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer
Lianidou et al. The role of CTCs as tumor biomarkers
Balic et al. Circulating tumor cells: from bench to bedside
Valtorta et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Zhang et al. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer
Negin et al. Circulating tumor cells in colorectal cancer: past, present, and future challenges
Kim et al. Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients
Reddy et al. Pulmonary venous blood sampling significantly increases the yield of circulating tumor cells in early-stage lung cancer
Wong et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients
Park et al. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma
Abdallah et al. MRP1 expression in CTCs confers resistance to irinotecan‐based chemotherapy in metastatic colorectal cancer
Werner et al. Expression of epithelial mesenchymal transition and cancer stem cell markers in circulating tumor cells
JP6485759B2 (ja) 末梢循環腫瘍細胞単位の悪性度の検出方法及びそのキット
van der Toom et al. Analogous detection of circulating tumor cells using the AccuCyte®—CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer
Yu et al. Application of circulating tumor cells and circulating free DNA from peripheral blood in the prognosis of advanced gastric cancer
Li et al. Circulating tumor cells are a good predictor of tumor recurrence in clinical patients with gastric cancer
Gristina et al. Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible
Manicone et al. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer
Kim et al. Detection of circulating tumor cells and their potential use as a biomarker for advanced renal cell carcinoma
Poggiana et al. Possible role of circulating tumor cells in early detection of lung cancer
Levy et al. Analysis of cell-free DNA to assess risk of tumoremia following endoscopic ultrasound fine-needle aspiration of pancreatic adenocarcinomas
Choi et al. KRAS mutation analysis by next‐generation sequencing in endoscopic ultrasound‐guided sampling for solid liver masses
Halawa et al. The role of liquid biopsy in the diagnosis and prognosis of WHO grade 4 astrocytoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928